- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Alvotech Q2 2026 Earnings Call Transcript | 4 | Benzinga.com | ||
| ALVOTECH SDR Aktie jetzt für 0€ handeln | |||||
| Mi | Alvotech reports 1H results | 7 | Seeking Alpha | ||
| Mi | Alvotech Announces Financial Results for the First Half of 2026 and Provides a Business Update | 139 | GlobeNewswire (Europe) | REYKJAVIK, ICELAND (August 19, 2026) - Alvotech (NASDAQ: ALVO; ALVO-SDB) ("Alvotech" or the "Company"), a global biotechnology company specializing in the development and manufacture of biosimilar... ► Artikel lesen | |
| Mi | Alvotech - 6-K, Report of foreign issuer | 5 | SEC Filings | ||
| Di | Alvotech Q2 2026 Earnings Preview | 4 | Seeking Alpha | ||
| 14.08. | Evercore ISI initiates Alvotech stock with outperform rating | 19 | Investing.com | ||
| 14.08. | Evercore ISI startet Coverage für Alvotech mit "Outperform"-Rating | 16 | Investing.com Deutsch | ||
| 10.08. | Alvotech to Report Financial Results for H1 2026 | 10 | GlobeNewswire (USA) | ||
| 29.07. | Alvotech - 6-K, Report of foreign issuer | 7 | SEC Filings | ||
| 29.07. | Alvotech announces successful closure of FDA inspection of manufacturing facility | 417 | GlobeNewswire (Europe) | REYKJAVIK, Iceland, July 29, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB) (the "Company"), a global biotechnology company specializing in the development and manufacture of biosimilar... ► Artikel lesen | |
| 17.07. | Novo, Alvotech face continued FDA scrutiny at plants tied to recent FDA rejections | 22 | FiercePharma | ||
| 03.07. | Alvotech: Transactions of Managers and Closely Associated Persons | 9 | GlobeNewswire (USA) | ||
| 02.07. | Alvotech S.A. - Increase in share capital | 394 | GlobeNewswire | With reference to an announcement published by Alvotech S.A. (symbol: ALVO) on June 18, 2026, the total nominal value of the company's listed share capital on Nasdaq Iceland hf. will be increased... ► Artikel lesen | |
| 01.07. | Alvotech - 6-K, Report of foreign issuer | 6 | SEC Filings | ||
| 01.07. | Biotech firm Alvotech expands capital access with $75M term loan facility | 11 | Seeking Alpha | ||
| 01.07. | Alvotech further strengthens liquidity by securing term loan facility of $75 million | 571 | GlobeNewswire (Europe) | $75 million additional term loan facility maturing December 31, 2027, led by GoldenTree Asset ManagementFollows recent $165m equity raise strengthening cash positionIncluding equity financing and... ► Artikel lesen | |
| 23.06. | Alvotech: Transactions of Managers and Closely Associated Persons | 13 | GlobeNewswire (USA) | ||
| 20.06. | Alvotech (ALVO): 10 Penny Stocks With Explosive Growth Potential | 9 | Insider Monkey | ||
| 18.06. | Amended: Alvotech Announces $125 Mln Public Offering, Concurrent Private Placement | 20 | RTTNews | ||
| 18.06. | Alvotech Announces IPO Of Shares And Concurrent Private Placement. Expects To Get $125 Mln | 718 | AFX News | REYKJAVIK (dpa-AFX) - Alvotech announces $125 mln IPO, Concurrent Private PlacementOn Thursday, Alvotech (ALVO), a biotechnology company based in Iceland, announced the commencement of the underwritten... ► Artikel lesen |
1 2 3 4 5 Weiter >>
88 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| LINEAGE CELL THERAPEUTICS | 0,934 | +1,41 % | Transcript: Lineage Cell Therapeutics Q1 2026 Earnings Conference Call | ||
| NOVOGENIA | 6,000 | 0,00 % | Novogenia baut neuen Standort in Hallwang | Die Novogenia AG hat mit dem Spatenstich den Bau ihrer neuen Firmenzentrale im österreichischen Hallwang begonnen. Auf mehr als 9.300 Quadratmetern entstehen dort Laborflächen, Produktionskapazitäten... ► Artikel lesen | |
| LYTIX BIOPHARMA | 0,688 | 0,00 % | LYTIX BIOPHARMA ASA: Lytix Biopharma Strengthens Business Development Leadership with Appointment of Timothy Herpin as Chief Business Officer | ||
| MODERNA | 113,70 | -0,37 % | BREAKING: AKTIONÄR-Depotwert Moderna explodiert! | Ein Durchbruch der mRNA-Technologie im Bereich der Onkologie: Moderna und der Entwicklungspartner Merck & Co haben die lang ersehnten ersten Ergebnisse der Phase-3-Studie INTerpath-001 mit Intismeran... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 39,640 | -0,05 % | Kaum zu fassen: Die unglaubliche Biotech-Story von Amylyx Pharmaceuticals | Der Biotech-Sektor ist immer wieder für faustdicke Überraschungen gut - sowohl negativ als auch positiv. Bei Amylyx Pharmaceuticals gibt es am Dienstag keine zwei Meinungen: Die Aktie des Biotech-Unternehmens... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 78,47 | 0,00 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution | - ARCALYST (rilonacept) Q2 2026 net product revenue of $243.6 million, representing ~55% year-over-year growth -- ARCALYST 2026 expected net product revenue increased to $980 - $995 million -- KPL-387... ► Artikel lesen | |
| QIAGEN | 38,735 | +3,05 % | DAX Gewinner am Mittwoch: Qiagen Aktie | Kursentwicklung und Chartanalyse | ||
| BIONTECH | 94,80 | -0,16 % | Schlafender Biotech-Riese vor der nächsten Wachstumsphase? BioNTech, Emyria und die neue Macht der Datenplattformen | ||
| PRAXIS PRECISION MEDICINES | 364,38 | -0,05 % | Raymond James raises Praxis Precision Medicines price target on pipeline outlook | ||
| APOGEE THERAPEUTICS | 134,78 | +0,02 % | AbbVie schließt Anleiheemission über 8,0 Mrd. US-Dollar zur Finanzierung der Übernahme von Apogee Therapeutics ab | ||
| NURIX THERAPEUTICS | 27,050 | 0,00 % | Biotech Stocks At 52-Week Highs - DCTH +22% On Q2 Results, ANRO, COAG, MNPR, NRIX | SOUTH SAN FRANCISCO (dpa-AFX) - The following biotech stocks reached 52-week highs on August 7, 2026, driven by key catalysts such as positive quarterly reports or upcoming conference participation.... ► Artikel lesen | |
| ADMA BIOLOGICS | 9,760 | 0,00 % | Kehoe Law Firm, P.C.: ADMA Biologics (ADMA) Shareholder Alert: Kehoe Law Firm Investigates Potential Fiduciary Duty Breaches | Philadelphia, Pennsylvania--(Newsfile Corp. - August 5, 2026) - Kehoe Law Firm, P.C. is investigating whether certain officers and directors of ADMA Biologics, Inc. ("ADMA," "ADMA Biologics," or... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 25,360 | +0,04 % | Arcutis Biotherapeutics, Inc.: Arcutis Expands Board of Directors with Appointment of Chris Peetz | WESTLAKE VILLAGE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovation in... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 12,430 | 0,00 % | Could Arcus Biosciences (RCUS) and Summit Therapeutics (SMMT)'s Cancer Drug Partnership Create a New Treatment Standard? | ||
| COGENT BIOSCIENCES | 35,310 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen |
Das Unternehmen ALVOTECH SDR kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +9,12 % bei einem Aktienkurs von 3,590 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALVOTECH SDR finden Sie auf Wallstreet Online.